Project Description

www.who.int

Background

The World Health Organization is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends.

In the global health system, the main international procurement agencies (The Global Fund, UNICEF, MSF, etc.) need quality products. The WHO’s prequalification process guarantees that products meet global standards of quality.

Ahimsa Partners was invited to participate in a panel of experts appointed in October 2011 to review the scope and effectiveness of the WHO’s prequalification program for medicines, vaccines and diagnostics. At the end of the review, the panel proposed that a strategic analysis be conducted to identify the program’s successes and failures as well as the main challenges and the opportunities for improving the process.

Aims and challenges

Study of the prequalification of diagnostics program:

The aim of the project was to identify realistic and viable ways to improve the prequalification of diagnostics program (PQDx), which primarily covered malaria and AIDS. To achieve its objective, the panel reviewed and examined the PQDx procedures currently in place and proposed improvements.

Ahimsa’s role

Leadership of the expert panel in studying the PQDx system.

The objective was to:

  • create a questionnaire focused on the procedure and its effectiveness and conduct a series of interviews with the various PQDx actors.
  • make a series of recommendations to the various stakeholders of the WHO’s prequalification program, procurement agencies and local regulatory authorities.
  • issue a final report containing various scenarios for improving the PQDx.

Results

The conclusions were presented to an Assistant Director-General of the WHO.

One of the report’s main recommendations was that the procedures and governance of the WHO’s PQDx program should be tightened.

The search for partners and funding to implement these recommendations is under way.

Testimonials

Merci encore pour ton travail exemplaire sur ce dossier.
Marie-Paule Kieny, Assistant Director-General – Innovation, Information, Evidence and Research, WHO

Félicitations pour le travail déjà accompli, qui est impressionnant!!!!
Virgile Pace, Technical Officer, WHO

I would like to thank you for the organization of this important moment, where we could all together share our thoughts and opinions that will probably contribute for a better pre-qualification process.
Carlos Gouveia, CBDL/Brazil

Your mediation with FDA and LSTHM is much appreciated.
Kees de Joncheere, Director Department of Essential Medicines and Health Products, WHO